ロード中...
A phase Ib study of the FGFR/VEGFR inhibitor dovitinib with gemcitabine and capecitabine in advanced solid tumor and pancreatic cancer patients
OBJECTIVES: Preclinical studies demonstrated antitumor activity of dovitinib in pancreatic cancer models. This phase Ib study aimed to determine the maximum tolerated dose of dovitinib in combination with gemcitabine and capecitabine and to characterize the safety and pharmacokinetic profile in pati...
保存先:
| 出版年: | Am J Clin Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6345595/ https://ncbi.nlm.nih.gov/pubmed/30418178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000492 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|